4 Jan 2024 • Addition of the macrolide clarithromycin to treatment with a β-lactam antibiotic in hospitalized patients with community-acquired pneumonia could improve early clinical response.

The recent ACCESS trial has demonstrated that adding clarithromycin to standard β-lactam antibiotic therapy significantly improves early clinical response & reduces the inflammatory burden.

The trial showed a 68% early response rate in the clarithromycin group compared to 38% in the placebo group, without increasing serious treatment-emergent adverse events.

Source: The Lancet | Read full story